

# Susanne Behr-Perst, PhD

Since 09/2021 *Head of Global Clinical Trials*  
Muscle Research Unit, Charité - Universitätsmedizin Berlin and the Max  
Delbrück Center for Molecular Medicine in the Helmholtz Society, Berlin,  
Germany  
Mentor: Prof. Dr. Simone Spuler

## Experience

2001 - 2021 Parexel International GmbH, Berlin – Clinical Research Organisation for Clinical  
Trials , Berlin, Germany:

11/2015 - 08/2021 *Senior Consultant – Regulatory Affairs*

03/2012 - 10/2015 *Consultant – Regulatory Affairs*

10/2007 - 03/2012 *Senior GxP Auditor*

05/2005 - 10/2007 *GxP Auditor II*

11/2004 - 05/2005 *GxP Auditor I*

10/2002 - 10/2004 *Project Manager for clinical trials (Phase I and II)*

05/2001 - 09/2002 *Quality Control Assistant Clinical Pharmacology*

09/2000 - 04/2001 *Free lancer Quality Control*

## Academic Training

10/1996 - 09/1998 Post-Doc-scholarship, Topic: Anti-infection prevention against tuberculosis  
Max-Planck-Institute for infection biology Berlin, Germany

04/1993 - 09/1996 Degree: Doctorate, Dr. rer. nat., Topic: The adhesion of lymphocytes to the  
secondary lymphatic tissue in situ  
University Hospital Rudolf Virchow of the Free University of Berlin, Germany

- 10/1988 - 09/1992 Degree: Graduate engineer for biotechnology, topic: splitting of a monoclonal antibody with papain and investigation of fragments  
Technical University of Applied Sciences Berlin, Germany
- 10/1987 - 04/1988 Natural science internship  
University of California San Francisco, USA
- 02/1985 - 07/1987 Degree: Medical-technical assistant for the laboratory  
Lette Verein Berlin, Germany

## Certificates

- 2007 Lean Six Sigma Yellow Belt  
2004 The Auditing Course, BARQA Cambridge, UK

## Memberships

- Since 1996 German Society for Immunology  
2005 - 2012 British Association of Research Quality Assurance (BARQA)

## Papers

- (1) **Behr S**, Munk M E, Schaberg T, Ulrichs T, Schulz R and Kaufmann S: Phenotypically activated gamma-delta T lymphocytes in the peripheral blood of patients with tuberculosis; The Journal of Infectious Diseases, 180 (May 1999), 141-9, 1999
- (2) **Behr S**, Korinth D and Schriever F: Differential adhesion pattern of B cell chronic lymphocyte leukemia cells; Leukemia, 12, (Jan. 1998), 71-77, 1998
- (3) Ulrichs T, Munk M E, Mollenkopf H, **Behr S**, Colangeli R, Gennaro M L and Kaufmann S: Differential T cell response to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors; Eur.J. Immunol., 1998, 28:3949 – 3958, 1998
- (4) Schriever F, Korinth D, Salah A, Lefterova P, Schmidt-Wolf I and **Behr S**: Human T lymphocytes bind to germinal centers of human tonsils via integrin alpha4 / VCAM-1 and LFA-1/ICAM-1 and -2; European Journal of Immunology, 27 (Oct. 1997), 35 – 39, 1997

- (5) **Behr S** and Schriever F: Engaging CD19 or target of an antiproliferative antibody on human B lymphocytes induces binding of B cells to the interfollicular stroma of human via integrin alpha4 / beta1 and fibronectin; The Journal of Experimental Medicine, 182 /Nov. 1995), 1191 – 1199, 1995
- (6) Roth R, Levin J and **Behr S**: A modified limulus amoebocyte lysate test with increased sensitivity for detection of bacterial endotoxin; The Journal of Laboratory and Clinical Medicine; 114 (Sep. 1989), 306 – 311, 1989